T 0419/16 (IL-33 antagonist antibody/MERCK SHARP & DOHME) of 24.06.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T041916.20240624
- Date of decision
- 24 June 2024
- Case number
- T 0419/16
- Petition for review of
- -
- Application number
- 05713577.4
- IPC class
- A61K 38/17C07K 16/28C07K 16/24A61P 25/02A61P 37/00A61P 11/06A61P 35/00A61K 38/20A61K 39/395A61P 19/02C07K 14/715A61P 31/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- T 0419/16 IL-33 antagonist antibodies/MSD 2022-02-03
- Abstracts for this decision
- Abstract on EPC2000 Art 087(1)
- Application title
- Use for Interleukin-33 (IL-33) and the IL-33 Receptor Complex
- Applicant name
- Merck Sharp & Dohme LLC
- Opponent name
- Regeneron Pharmaceuticals, Inc.
Strawman Limited
Gray, Tony
Takeda California, Inc.
Sanofi - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 87(1)
- Keywords
- Priority - (yes)
Novelty - auxiliary request 1 (yes)
Inventive step - auxiliary request 1 (yes) - Catchword
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent in amended form with the following claims, and a description and drawings to be adapted thereto as necessary:
claims 1 and 2 of auxiliary request 1, filed with the respondent's reply to the statements of grounds of appeal.